Increased Mortality Risk in Patients With Phenotypic Hereditary Hemochromatosis But Not in Their First-Degree Relatives

Gastroenterology

Volumn 137, Issue 4, 2009, Pages 1301-1309

  Elmberg, Maria ^a   Hultcrantz, Rolf ^a   Ebrahim, Fereshte ^g   Olsson, Sigvard ^b   Lindgren, Stefan ^c   Lööf, Lars ^d   Stål, Per ^a   Wallerstedt, Sven ^b   Almer, Sven ^e   Sandberg Gertzén, Hanna ^f   Ekbom, Anders ^a   Askling, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d CENTRAL HOSPITAL   (Sweden)

^e IKE   (Sweden)

^f ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^g CENTRE FOR EPIDEMIOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HEMOCHROMATOSIS; HEREDITARY HEMOCHROMATOSIS; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; REGISTER; RELATIVE; RISK ASSESSMENT; SPOUSE; SWEDEN; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; GENETIC PREDISPOSITION; GENETICS; HEALTH SURVEY; MIDDLE AGED; PEDIGREE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS;

IRON;

ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEMOCHROMATOSIS; HOSPITALIZATION; HUMANS; IRON; MALE; MIDDLE AGED; PEDIGREE; PHENOTYPE; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SWEDEN;

EID: 70349435372     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.07.038     Document Type: Article

References (45)

1. Hanson E.H., Imperatore G., and Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol 154 (2001) 193-206
2. Yang Q., McDonnell S.M., Khoury M.J., et al. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of multiple-cause mortality data. Ann Intern Med 129 (1998) 946-953
3. Crooks C.J., West J., Solaymani-Dodaran M., et al. The epidemiology of haemochromatosis-a population based study. Aliment Pharmacol Ther 29 (2009) 183-192
4. Niederau C., Fischer R., Sonnenberg A., et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 313 (1985) 1256-1262
5. Milman N., Pedersen P., Steig T., et al. Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. Ann Hematol 80 (2001) 737-744
6. Cardoso E.M., Stal P., Hagen K., et al. HFE mutations in patients with hereditary haemochromatosis in Sweden. J Intern Med 243 (1998) 203-208
7. Jouanolle A.M., Fergelot P., Gandon G., et al. A candidate gene for hemochromatosis: frequency of the C282Y and H63D mutations. Hum Genet 100 (1997) 544-547
8. Nielsen P., Carpinteiro S., Fischer R., et al. Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany. Br J Haematol 103 (1998) 842-845
9. de Valk B., and Marx J.J. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med 159 (1999) 1542-1548
10. Gutteridge J.M. Iron and oxygen radicals in brain. Ann Neurol 32 Suppl (1992) S16-S21
11. Valko M., Izakovic M., Mazur M., et al. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 266 (2004) 37-56
12. Moalem S., Weinberg E.D., and Percy M.E. Hemochromatosis and the enigma of misplaced iron: implications for infectious disease and survival. Biometals 17 (2004) 135-139
13. Adams P.C., Reboussin D.M., Barton J.C., et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 352 (2005) 1769-1778
14. Bulaj Z.J., Griffen L.M., Jorde L.B., et al. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 335 (1996) 1799-1805
15. Burt M.J., George P.M., Upton J.D., et al. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut 43 (1998) 830-836
16. Chambers V., Sutherland L., Palmer K., et al. Haemochromatosis-associated HFE genotypes in English blood donors: age-related frequency and biochemical expression. J Hepatol 39 (2003) 925-931
17. de Valk B., Addicks M.A., Gosriwatana I., et al. Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes. Eur J Clin Invest 30 (2000) 248-251
18. de Valk B., Witlox R.S., van der Schouw Y.T., et al. Biochemical expression of heterozygous hereditary hemochromatosis. Eur J Intern Med 11 (2000) 317-321
19. Jackson H.A., Carter K., Darke C., et al. HFE mutations, iron deficiency and overload in 10,500 blood donors. Br J Haematol 114 (2001) 474-484
20. Merryweather-Clarke A.T., Worwood M., Parkinson L., et al. The effect of HFE mutations on serum ferritin and transferrin saturation in the Jersey population. Br J Haematol 101 (1998) 369-373
21. Njajou O.T., Houwing-Duistermaat J.J., Osborne R.H., et al. A population-based study of the effect of the HFE C282Y and H63D mutations on iron metabolism. Eur J Hum Genet 11 (2003) 225-231
22. Phatak P.D., Ryan D.H., Cappuccio J., et al. Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients. Blood Cells Mol Dis 29 (2002) 41-47
23. Waalen J., Felitti V., Gelbart T., et al. Penetrance of hemochromatosis. Blood Cells Mol Dis 29 (2002) 418-432
24. McCune C.A., Ravine D., Carter K., et al. Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients. Gut 55 (2006) 554-562
25. Whiting P.W., Fletcher L.M., Dixon J.K., et al. Concordance of iron indices in homozygote and heterozygote sibling pairs in hemochromatosis families: implications for family screening. J Hepatol 37 (2002) 309-314
26. Jacobs E.M., Hendriks J.C., Marx J.J., et al. Morbidity and mortality in first-degree relatives of C282Y homozygous probands with clinically detected haemochromatosis compared with the general population: the HEmochromatosis FAmily Study (HEFAS). Neth J Med 65 (2007) 425-433
27. Jacobs E.M., Hendriks J.C., van Deursen C.T., et al. Severity of iron overload of proband determines serum ferritin levels in families with HFE-related hemochromatosis: the HEmochromatosis FAmily Study. J Hepatol 50 (2009) 174-183
28. Lazarescu A., Snively B.M., and Adams P.C. Phenotype variation in C282Y homozygotes for the hemochromatosis gene. Clin Gastroenterol Hepatol 3 (2005) 1043-1046
29. Niederau C., Fischer R., Purschel A., et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 110 (1996) 1107-1119
30. Bathum L., Christiansen L., Nybo H., et al. Association of mutations in the hemochromatosis gene with shorter life expectancy. Arch Intern Med 161 (2001) 2441-2444
31. Waalen J., Nordestgaard B.G., and Beutler E. The penetrance of hereditary hemochromatosis. Best Pract Res Clin Haematol 18 (2005) 203-220
32. Van Aken M.O., De Craen A.J., Gussekloo J., et al. No increase in mortality and morbidity among carriers of the C282Y mutation of the hereditary haemochromatosis gene in the oldest old: the Leiden 85-plus study. Eur J Clin Invest 32 (2002) 750-754
33. Beutler E., Felitti V.J., Koziol J.A., et al. Penetrance of 845G-> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 359 (2002) 211-218
34. Lunde A.S., Lundeborg S., Lettenstrom G.S., et al. The person-number systems of Sweden, Norway, Denmark, and Israel. Vital Health Stat 2 84 (1980) 1-59
35. Elmberg M., Hultcrantz R., Ekbom A., et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 125 (2003) 1733-1741
36. Andersen R.V., Tybjaerg-Hansen A., Appleyard M., et al. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 103 (2004) 2914-2919
37. Gurrin L.C., Osborne N.J., Constantine C.C., et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology 135 (2008) 1945-1952
38. Yang Q., McDonnell S.M., Khoury M.J., et al. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of multiple-cause mortality data. Ann Intern Med 129 (1998) 946-953
39. Willis G., Wimperis J.Z., Smith K.C., et al. Haemochromatosis gene C282Y homozygotes in an elderly male population. Lancet 354 (1999) 221-222
40. Gutteridge J.M., Rowley D.A., Griffiths E., et al. Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin Sci (Lond) 68 (1985) 463-467
41. Edwards C.Q., Griffen L.M., Goldgar D., et al. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 318 (1988) 1355-1362
42. Waalen J., and Beutler E. No age-related decrease in frequency of heterozygotes for the HFE C282Y haemochromatosis mutation. J Hepatol 40 (2004) 1044-1045
43. Pankow J.S., Boerwinkle E., Adams P.C., et al. HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study. Transl Res 152 (2008) 3-10
44. Centre for Epidemiology NBoHaW. The Swedish Inpatient Register 1987-1995 (1997), National Board of Health and Welfare, Stockholm, Sweden
45. Wojcik J.P., Speechley M.R., Kertesz A.E., et al. Natural history of C282Y homozygotes for hemochromatosis. Can J Gastroenterol 16 (2002) 297-302